Partnering

Turn retinal assets into long‑acting therapies same molecule, fewer injections

NAAmatrix™ unlocks multibillion dollars in value and saves vision

Defend & extend:

Long‑acting life cycle management and line extensions that protect price and market share

Differentiate from competitors / biosimilars

On treatment outcomes, efficacy, and burden, not on price

Expand treatment;

Recapture patient drop‑outs. Switch high‑burden patients

Earlier intervention:

Diabetic Retinopathy & Geography Atrophy. Where treatment intensity is not viable or limits adoption

Indications:

  • Geographic Atrophy
  • Neovascular AMD
  • Retinal Fibrosis
  • Diabetic Retinopathy
  • Retinopathy of Prematurity

Modalities:

  • Small molecules
  • Antibodies
  • Proteins
  • Peptides

Together, we can drive transformative progress in ophthalmic care.

If you are interested in exploring partnership opportunities or learning more about our technology, we invite you to connect with us via the contact form below.